Geneva – Following the voluntary licensing agreement between the Medicines Patent Pool and ViiV Healthcare in late 2020, there has been notable progress in Azerbaijan, Belarus, and Kazakhstan regarding the transition to dolutegravir (DTG)-based treatments for HIV. By June 2024, the concerted efforts of various stakeholders have led to significant price reductions and the procurement of treatment volumes that promise to cover a substantial percentage of individuals on antiretroviral treatment (ART).